Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07459634) titled 'A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC' on March 5.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Jazz Pharmaceuticals
Condition:
Extensive-stage Small-cell Lung Cancer
Intervention:
Drug: Lurbinectedin
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: April 25, 2026
Target Sample Size: 50
Countries of Recruitment:
United States
To know more, visit https://clinicaltrials.gov/study/NCT...